Patrick Schöffski

Research interests

Publications

• Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

  New England Journal of Medicine · 2024 · 10.1056/nejmoa2407417

• Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

  Zurich Open Repository and Archive (University of Zurich) · 2022 · 10.5167/uzh-213514

• Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.09.005

• Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2021 · 10.1016/j.annonc.2021.08.1995

• Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.07.006

• Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study

  The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30451-4

• Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30168-6

• Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1910836

• Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy310

• Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy095

• Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · 10.1093/annonc/mdy096

• Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30900-2

• Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

  The Lancet · 2016 · 10.1016/s0140-6736(15)01283-0

• Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70063-4

• Cabozantinib in Progressive Medullary Thyroid Cancer

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.48.4659

• Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

  The Lancet · 2012 · 10.1016/s0140-6736(12)60651-5

• Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

  The Lancet · 2012 · 10.1016/s0140-6736(12)61857-1

• Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

  Journal of Clinical Oncology · 2012 · 10.1200/jco.2012.45.0494

• MYC High Level Gene Amplification Is a Distinctive Feature of Angiosarcomas after Irradiation or Chronic Lymphedema

  American Journal Of Pathology · 2009 · 10.2353/ajpath.2010.090637

• Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.21.3223

• Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

  The Lancet Oncology · 2009 · 10.1016/s1470-2045(09)70162-7

• XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2004 · 10.1200/jco.2004.11.069

• Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer

  Journal of Clinical Oncology · 2004 · 10.1200/jco.2004.10.112

• Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients

  Annals of Oncology · 2002 · 10.1093/annonc/mdf034

• Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data

  European Journal of Nuclear Medicine and Molecular Imaging · 2001 · 10.1007/s002590100639

Current projects

No projects listed.